Article Text

other Versions

PDF
Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas
  1. Cristiana B Nunes (cristianabnunes{at}gmail.com)
  1. Federal University of Minas Gerais, Brazil
    1. Rafael Malagoli Rocha (rafael.malagoli{at}gmail.com)
    1. Federal University of Minas Gerais, Brazil
      1. Jorge S Reis-Filho (jsreis{at}hotmail.com)
      1. The Breakthrough Breast Cancer Research Centre, United Kingdom
        1. Maryou Lambros (maryou.lambros{at}icr.ac.uk)
        1. The Breakthrough Breast Cancer Research Centre, United Kingdom
          1. Gislene F S Rocha (gislene.fatima{at}gmail.com)
          1. Federal University of Minas Gerais, Brazil
            1. Fernanda S F Sanches (nandasan{at}uai.com.br)
            1. Federal University of Minas Gerais, Brazil
              1. Flavio N Oliveira (flavinho.nepomuceno{at}gmail.com)
              1. Federal University of Minas Gerais, Brazil
                1. Helenice Gobbi (helenicegobbi{at}gmail.com)
                1. Federal University of Minas Gerais, Brazil

                  Abstract

                  Aims: We compared the ¡¥sensitivity¡¦ and ¡¥specificity¡¦ of new rabbit monoclonal antibody SP3 with those of mouse monoclonal and rabbit polyclonal antibodies to detect HER2 amplification as defined by chromogenic in situ hybridization (CISH). Methods and Results: Serial sections from tissue microarrays (TMAs) containing 84 breast carcinomas were submitted to CISH (Zymed HER2 Spot-Light„¥ kit) and immunohistochemistry, using NeoMarkers SP3 (rabbit monoclonal), DAKO A0485 and DAKO HercepTest (polyclonal), Novocastra NCL-CB11, Cell Marque CM-CB11, and Genentech 4D5 (mouse monoclonal). The best antibody concordance was between SP3 and HercepTest (kappa=0.74). SP3, A0485 and HercepTest detected all HER2 amplified tumours, but were less ¡¥specific¡¦ than mouse monoclonal antibodies. There were 3/38 (7.9%) and 8/38 (21.0%) of non-amplified tumours scored as 3+ using SP3 and A0485, respectively. 3/46 (6.5%) of amplified tumours were negative for NCL-CB11. SP3, HercepTest and A0485 showed no gene amplification on 55%, 62.5% and 92.3% of the 2+ scored tumours, but most of the 2+ scored tumours using monoclonal antibodies were amplified by CISH (80% to 92.3%). Conclusions: SP3 is more ¡¥sensitive¡¦ than mouse monoclonal antibodies for Her2 assessment. However, HercepTest, CB11 and 4D5 show higher ¡¥specificity¡¦ than SP3 for the identification of HER2 gene amplification. Mouse monoclonal antibodies show less Her2 2+ tumours and most of them are amplified by CISH. Word-count: 212

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.